PET-CT
44
23
23
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
2.3%
1 terminated out of 44 trials
85.7%
-0.8% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (44)
Performance of Amino Acid Positons Emission Tomography in Brain Metastases
DLL3-Targeted PET/CT in Small Cell Lung Cancer
Dual-tracer PET Radiomics for Prostate Cancer Stratification
Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors
FAP-targeted PET/NIR in Lung Malignant Tumors
68Ga FAPI PET/CT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer
PET-CT in Lymphoma Among the Eldery
Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study
68Ga-XACP3 PET/CT in Prostate Cancer
PET/CT for Trop2 ADC Response Evaluation NSCLC
[18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer
68Ga-DOTA-hLAG-3 PET Imaging of LAG-3 Expression in Cancers
PET/CT for Trop2 ADC Response Evaluation Cancers
68Ga-MY6349 PET/CT in Solid Tumors
CXCR4-targeted PET/CT Imaging in Hematological Malignancies
68Ga-FAPI PET/CT in Malignant Tumors
Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma
Added Value of PET/CT in Assessment of Hepatocellular Malignancy Post Radiofrequency Ablation
Integrin αvβ6-targeted PET in Malignant Tumors
Granzyme B-targeted PET Imaging Monitoring Tumor Responses to Immunotherapy